AU2001267823A1 - Compounds exhibiting x-type spla2 inhibiting effect - Google Patents

Compounds exhibiting x-type spla2 inhibiting effect

Info

Publication number
AU2001267823A1
AU2001267823A1 AU2001267823A AU6782301A AU2001267823A1 AU 2001267823 A1 AU2001267823 A1 AU 2001267823A1 AU 2001267823 A AU2001267823 A AU 2001267823A AU 6782301 A AU6782301 A AU 6782301A AU 2001267823 A1 AU2001267823 A1 AU 2001267823A1
Authority
AU
Australia
Prior art keywords
inhibiting effect
compounds exhibiting
type spla2
spla2
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267823A
Inventor
Kohji Hanasaki
Minoru Ikeda
Tomoyuki Ogawa
Takashi Ono
Kaoru Seno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2001267823A1 publication Critical patent/AU2001267823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
AU2001267823A 2000-06-29 2001-06-27 Compounds exhibiting x-type spla2 inhibiting effect Abandoned AU2001267823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000195430 2000-06-29
JP2000-195430 2000-06-29
PCT/JP2001/005479 WO2002000621A1 (en) 2000-06-29 2001-06-27 Compounds exhibiting x-type spla2 inhibiting effect

Publications (1)

Publication Number Publication Date
AU2001267823A1 true AU2001267823A1 (en) 2002-01-08

Family

ID=18694092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267823A Abandoned AU2001267823A1 (en) 2000-06-29 2001-06-27 Compounds exhibiting x-type spla2 inhibiting effect

Country Status (4)

Country Link
US (3) US7026318B2 (en)
JP (1) JPWO2002000621A1 (en)
AU (1) AU2001267823A1 (en)
WO (1) WO2002000621A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI314457B (en) * 2001-03-19 2009-09-11 Shionogi & Co
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
DK1581535T5 (en) * 2003-01-09 2009-12-21 Astellas Pharma Inc pyrrolopyridazine
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
JP2007519605A (en) * 2004-01-30 2007-07-19 日本たばこ産業株式会社 Appetite suppressant
DE602005026867D1 (en) * 2005-01-19 2011-04-21 Biolipox Ab INFLAMMATORY INDOL DERIVATIVES
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5205971B2 (en) * 2006-01-27 2013-06-05 宇部興産株式会社 Method for producing tetrahydropyran compound
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN102137858B (en) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-lipoxygenase-activating protein inhibitor
DE202009003977U1 (en) 2009-03-24 2009-07-30 Horst E. Otten Matratzenfabrik Gmbh Adjustment mechanism, especially for slatted frames and beds
CA2759176C (en) 2009-04-29 2016-03-15 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PL2707101T3 (en) 2011-05-12 2019-10-31 Proteostasis Therapeutics Inc Proteostasis regulators
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP2018526440A (en) * 2015-08-31 2018-09-13 ディアキュレートＤｉａｃｃｕｒａｔｅ Use of indole compounds to stimulate the immune system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
DE69527322T2 (en) * 1994-04-01 2003-02-27 Lilly Co Eli 1H-indole-3-glyoxylamide sPLA2 inhibitors
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
JPH10505584A (en) 1994-07-21 1998-06-02 イーライ・リリー・アンド・カンパニー Indolizine sPLA (2) Inhibitor
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
JP2000502083A (en) 1995-12-13 2000-02-22 イーライ・リリー・アンド・カンパニー sPLA (2) Naphthylglyoxamides as inhibitors
JP2000501739A (en) 1995-12-13 2000-02-15 イーライ・リリー・アンド・カンパニー sPLA (2) Naphthylacetamide as an inhibitor
BR9713261A (en) 1996-10-30 2000-03-28 Lilly Co Eli Tricyclics replaced
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
ID18983A (en) 1996-12-04 1998-05-28 Lilly Co Eli PIRAZOLA AS AN NON-PANCREAS PHOSPHOLIPASE SECRETARY SECRESSION IN HUMAN
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
EP0987250A4 (en) 1997-02-20 2000-12-06 Shionogi & Co Indole dicarboxylic acid derivatives
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
JP2001517707A (en) * 1997-09-26 2001-10-09 イーライ・リリー・アンド・カンパニー Methods for treating cystic fibrosis
CA2310249A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
CA2326522A1 (en) * 1998-03-31 1999-10-14 Shionogi & Co., Ltd. Pyrrolo[1,2-a]pyrazine spla2 inhibitor
EP1084108A4 (en) * 1998-05-01 2005-01-12 Lilly Co Eli Spla 2? inhibitor compounds for treatment of disease
BR9911048A (en) * 1998-05-21 2001-02-06 Shionogi & Co Pyrrole spla2 inhibitor [1,2-b] pyridazine
US6384041B1 (en) 1998-06-30 2002-05-07 Eli Lilly And Company Bicyclic sPLA2 inhibitors
CA2346334A1 (en) * 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
TWI314457B (en) * 2001-03-19 2009-09-11 Shionogi & Co

Also Published As

Publication number Publication date
US20060116379A1 (en) 2006-06-01
JPWO2002000621A1 (en) 2004-04-22
US20090286796A1 (en) 2009-11-19
US20030181454A1 (en) 2003-09-25
US7026318B2 (en) 2006-04-11
WO2002000621A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2001241128A1 (en) Novel amide compounds
AU2001258771A1 (en) -secretase inhibitors
AU2002225730A1 (en) Compounds
AU2001274009A1 (en) Substituted indoles as parp inhibitors
AU4878601A (en) Aromatic amide compounds
AU2002218266A1 (en) Novel indanylidene compounds
AU2001286243A1 (en) Tetrahydroquinoline compounds
AU2001292518A1 (en) Novel compounds
AU2001267823A1 (en) Compounds exhibiting x-type spla2 inhibiting effect
AU2001266345A1 (en) Five-membered-ring compound
AU4430701A (en) Compounds for targeting
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001239765A1 (en) Novel compounds
AU2001246998A1 (en) Novel compounds
AU2001230605A1 (en) Apoptosis inhibitor
AU2001253362A1 (en) Novel compounds
AU2001244562A1 (en) Neovascularization inhibitors
AU3997700A (en) Anti-first-pass effect compounds
AU2002231077A1 (en) Novel compounds
AU2001260661A1 (en) Compounds exhibiting thrombopoietin-like activities
AU2001278086A1 (en) Pseudo addressing
AU2001256964A1 (en) Novel compounds
AU2002225724A1 (en) Motilide compounds
AU2002217285A1 (en) Compounds
AU2001230689A1 (en) Novel compounds